替诺福韦酯挽救治疗对核苷（酸）类药物耐药的慢性乙型肝炎研究进展

doi:10.3969/j.issn.1672-5069.2016.03.032

Abstract

Abstract: The nucleoside/nucleotide analogues have been widely used in the treatment of patients with chronic hepatitis B，and tenofovir disoproxil fumarate （TDF） has the characteristics of high safety and low resistance，and has been administered for naive chronic hepatitis B（CHB），non-responded hepatitis B，and even patients with cirrhosis with decompensated liver function. The authors summarize the therapeutic effect of TDF in rescue treatment of patients with CHB resistant to lamivudine，adefovir dipivoxil，and entecavir.

Key words: Chronic hepatitis B, Tenofovir, Nucleos（t）ides, Drug resistance, Rescue therapy

Lu Ting,Li Chengzhong. Rescue therapy of tenofovir disoproxil fumarate in hepatitis B patients with nucleoside/nucleotide analogue resistant[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(3): 369-372.

References

[1] Malekzadeh R，Mohamadnejad M，Rakhshani N，et al. Reversibility of cirrhosis in chronic hepatitis B. Clin Gastroenterol Hepatol，2004，2（3）:344-347.
[2] Chang TT，Lai CL，Chien RN，et a1．Four years of lamivudine treatment in Chinese patients with chronic hepatitis B.J Gastroenteml Hepatol，2004，19:1276-1282．
[3] Marcellin P，Heathcote EJ，Buti M，et a1. Tenofovir disopmxil fumarate versus adefovir dipivoxil for chronic hepatitis B.N Engl J Med，2008，359:2442-2455．
[4] DeChristoforo R，Penzak SR.Tenofovir:a nucleotide anakogue reversese inhibitor for treatment of HIV infection.Am I Health Syst Pharm，2004，61（1）:86-98.
[5] Villet S，Pichoud C，Villeneuve J P，et al. Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient. Gastroenterology，2006，131（4）:1253-1261.
[6] VanBmmel F，Trojan J，Deterding K，et al. Evolution of adefovir-resistant HBV polymerase gene variants after switching to tenofovir disoproxil fumarate monotherapy.Antivir Ther，2012，17（6）:1049-105.
[7] Schildgen O，Sirma H，Funk A，et al.Variant of hepatitis B virus with primary resistance to adefovir. N Engl J Med，2008，354（17）:1807-1812.
[8] Tan J，Degertekin B，Wong SN，et al.Tenofovir monotherary is effective treatment failure toadefovir in the absence of adefovir-resistant mutation. J Hepatol，2008，48（3）:391-398.
[9] Van Bmmel F，Zllner B，Sarrazin C，et al.Tenofovir for patients with lamivdine-resistent hepatitis B virus （HBV）infection and high HBV DNA level during adefovir therapy.Hepatology，2006，44:318-325.
[10] Patterson SJ，Georqe J，Strasser SI，et al. Tenofovir disoproxil fumarate rescure therapy following failure of both lamivudine and adefovir disoproxil in chronic hepatitis B.Gut，2011，60（2）:247-254.
[11] Manns M，Heathcote J，Marcellin P，et al.Efficacy of tenofovir DF treatment in patients with a suboptimal response to adefovir dipivoxil.45th Annual Meeting of the Eurppean Association for the Study of the Liver（EASL2010），Vienna，Austria，2010:14-18.
[12] Levrero M，Cimino L，Lampertico P，et al.OPTIB-A multicenter prospective open label study on tenofovir（TDF） for chronic hepatitis B paients with suboptimal response to ADV or ADV/LAM treatment.J Hepatol，2010，52（S1）:S390.
[13] Berg T，Marcellin P，Zoulim F，et a1.Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic hepatitis B virus infection. Gastroenterology，2010，139（4）:1207-1217．
[14] Van Bmmel F，de Man RA，Wedemeyer H，et a1.Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nuc1eoside/nuc1eotide analogues.Hepatology，2010，51（1）:73-80．
[15] Sherman M，Yurdaydin C，Sollano J，et al. Entercavir for treatment of Lamivudine-refractory，HBeAg-positive chronic hepatitis B.Gastroenterology，2006，130:2039-2049.
[16] 任红. 亚太肝病学会慢性乙型肝炎管理指南（2008年版）解读. 中华肝脏病杂志，2008，16（4）:243-246.
[17] Pan CQ，Hu KQ，Yu AS，et al. Entecavir plus tenofovir monotherapy in chronic hepatitis B patients with prior suboptimal response to entecavir. J Viral Hepat，2012，19（3）:213-219.
[18] Leemans WF，Niesters HG，van der Eijk AA，et al.Selection of an entecavir-resistant mutant despite prolonged hepatitis B virus DNA suppression，in a chronic hepatitis B patient with preexistent lamivudine resistance:successful rescue therapy with tenofovir. Eur J Gastroenterol Hepatol，2008，20（8）:773-777
[19] Sarrecchia C，Svicher V，Volpi A，et al. Successful switch to tenofovir after suboptimal response to entecavir in an immunocompromised patient with chronic hepatitis B and without genotypic hepatitis B virus resistance. Infection，2011，39（4）:367-370.
[20] Seto WK，Yuen MF.Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B monoinfection. Hepatol Int，2011，19:23.
[21] Snoe-Lampart A，Chappell B，Curtis M，et al.No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of thropy in patients monoinfected with chronic hepatitis B virus.Hepetology，2011，53（3）:763-773.
[22] Heathcote EJ，Marcellin P，Buti M，et al.Three-year efficacy and safty of tenofovir disoproxil fumarate treatment for chronic hepatitis B.Gastroenterology，2011，140（1）:132-143.
[23] Kim WR，Loomba R，Berq T，et al. Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B. Cancer，2015，ahead of print.
[24] Ahn SS，Chon YE，Kim BK， et al.Tenofovir disoproxil fumarate monotherapy for nucleos（t）ide-naive chronic hepatitis B patients in Korea:data from the clinical practice setting in a single-center cohort.Clin Mol Hepatol，2014，20（3）:261-266.
[25] Seto WK，Liu K.Patterns of hepatitis B surface antigen decline and HBV DNA suppression in Asian treatment-experienced chronic hepatitis B patients after three years of tenofovir treatment. J Hepatol，2013，59（4）:709-716.
[26] Peters MG，Andersen J，Lynch P，et a1. Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection:ACTGA5127. Hepatology，2006，44（5）:1110-1116．
[27] 王陆军，张纪元，冯国华，等.替诺福韦酯治疗慢性乙型肝炎的最新进展. 传染病信息，2011，24（4）:255-256．
[28] Heathcote EJ，Marcellin P，Buti M，et a1.Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B.Gastroenterology，2011，140（1）:132-143．
[29] HeathcoteJ，Gane E，DeMan R，et al. A randomized，double-blind， comparison of tenofovir DF（TDF） versus adefovir dipivoxil（ADV） for the treatment of HBeAg positive chronic hepatitis B（CHB）:study GS-US-174-0103.AASLD，2007，Abstract LB6.
[30] Marcellin P，Buti M，Krastev Z，et al. A randomized，double-blind，comparison of tenofovir DF （TDF） versus adefovir dipivoxil（ADV）for the treatment of HBeAg-negative chronic hepatitis B（CHB）:study GS-US-174-0102. 58th annual meeting of the American Association for the Study of Liver Diseases（AASLD 2007）. Boston，November 2-6，2007，Abstract LB2.
[31] Bhattacharya D，Thio CL.Review of hepatitis B therapeutics.Clin Infect Dis，2010，1（101）:1201-1208.
[32] Jo K，Dodge JL，Wadley A，et al.HBeAg seroconversion is lower in asian versus non-asian patients during treatment of chronic hepatitis B with tenofovir or entecavir. Hepatology，2013，58（4S）:669A.

Rescue therapy of tenofovir disoproxil fumarate in hepatitis B patients with nucleoside/nucleotide analogue resistant

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	chronic hepatitis B Zhu Lingyun, Zhang Maohai Cui Shasha, et al.. Serum IL-12 and IL-18 levels as well as peripheral blood mononuclear cell FOXp3 in patients with [J]. Journal of Practical Hepatology, 2019, 22(6): 816-819.
[2]	patients with chronic hepatitis B Zhang Yingming, Shen Shuang, Tian Fei, et al.. Prediction of response to peginterferon alfa-2a by blood IFNL4 and IL-28B gene polymorphisms in [J]. Journal of Practical Hepatology, 2019, 22(6): 828-831.
[3]	Ma Liying, Shen Lijuan.. Efficacy and safety of tenofovir in the treatment of pregnant women with high HBV DNA loads [J]. Journal of Practical Hepatology, 2019, 22(6): 836-839.
[4]	Zhao Xieshan, Wu Chunrong, Wang Chunfeng, et al. Preliminary study on the efficacy of combination of tenofovir and Anluo Huaxian pill in the treatment of patients with HBeAg-negative chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 644-647.
[5]	Gao Wei, Hou Yong. Diagnostic efficacy of hepatic fibrosis by liver stiffness measurement in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 652-655.
[6]	Bai Yichun, Deng Jihong, Mei Xiaoping. Efficacy of peginterferon alfa-2b treatment and affecting response factors in patients with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 490-493.
[7]	Zhang Yafei, Ye Jun, Xie Qinxiu, et al. Difference in predicting efficacy of significant liver fibrosis by noninvasive liver fibrosis index in different hospitals [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 510-513.
[8]	Wang Baodan, Li Meng, Gao Yu. Predictive factors of response to interferon-α antiviral therapy in children with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 345-348.
[9]	Yang Ruixi, Liu Mingxin, Chen Lingxi. Efficacy and safety of tenofovir disoproxil fumarate and entecavir in the treatment of chronic hepatitis B patients with viral DNA polymerase 204 site mutation infection [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 349-352.
[10]	Jiang Yi, Liu Bing. Comparison of clinical features and histopathological activity index between patients with chronic hepatitis B and chronic hepatitis C [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 188-191.
[11]	Zhang Huanhuan, Yang Huan, Shen Silan, et al.. Distribution of HBV genotypes and drug-resistant mutations in patients with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 41-44.
[12]	Hu Hulan, Zhu Mengfei, Shi Junping.. Non-alcoholic fatty liver disease with concurrent chronic hepatitis B: What’s the progress [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 149-152.
[13]	Wang Yaofeng.. Efficacy and safety of tenofovir in the treatment of patients with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 847-850.
[14]	Huang Chunming, Yang Zhan, Nie Yuqiang, et al.. Prediction of liver fibrosis by gamma-glutamyl-transpeptidase-to-platelet ratio in patients with chronic hepatitis B viral infection with normal serum transaminase levels [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 859-862.
[15]	Baoyan, Wang Yun, Xiang Xiaogang, et al.. Prognosis of patients with hepatocellular carcinoma and underlying hepatitis B An [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 924-927.